Moreover, LGD1069 (RXR agonist) and Am580 (RARα agonist) reduced oxidative stress, promoted glucose utilization and protein kinase B (Akt) activation, improved insulin resistance, and promoted diabetes-induced cardiac dysfunction and pathological changes via enhancing glucose tolerance. This evidence concerns the gene AKT1 and diabetes mellitus.